AR072524A1 - Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos - Google Patents

Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos

Info

Publication number
AR072524A1
AR072524A1 ARP090102740A ARP090102740A AR072524A1 AR 072524 A1 AR072524 A1 AR 072524A1 AR P090102740 A ARP090102740 A AR P090102740A AR P090102740 A ARP090102740 A AR P090102740A AR 072524 A1 AR072524 A1 AR 072524A1
Authority
AR
Argentina
Prior art keywords
seq
treatment
mammalian
beta defensin
beta
Prior art date
Application number
ARP090102740A
Other languages
English (en)
Spanish (es)
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR072524(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes As filed Critical Novozymes As
Publication of AR072524A1 publication Critical patent/AR072524A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP090102740A 2008-07-18 2009-07-17 Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos AR072524A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP08160761 2008-07-18
EP08162486 2008-08-15
EP08163614 2008-09-03
EP09160448 2009-05-15

Publications (1)

Publication Number Publication Date
AR072524A1 true AR072524A1 (es) 2010-09-01

Family

ID=41445843

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090102740A AR072524A1 (es) 2008-07-18 2009-07-17 Tratamiento de enfermedades inflamatorias con beta defensinas de mamiferos

Country Status (18)

Country Link
US (1) US20100016232A1 (enExample)
EP (1) EP2320929B1 (enExample)
JP (1) JP2011528332A (enExample)
KR (2) KR20110044863A (enExample)
CN (1) CN102159232A (enExample)
AP (1) AP2011005537A0 (enExample)
AR (1) AR072524A1 (enExample)
AU (1) AU2009272680A1 (enExample)
BR (1) BRPI0915780A2 (enExample)
CA (1) CA2730674A1 (enExample)
CL (1) CL2011000098A1 (enExample)
EA (1) EA201170218A1 (enExample)
IL (1) IL210714A0 (enExample)
MX (1) MX2011000569A (enExample)
NZ (1) NZ590466A (enExample)
TW (1) TW201004641A (enExample)
WO (1) WO2010007165A2 (enExample)
ZA (1) ZA201100462B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
CN102247591A (zh) * 2008-07-18 2011-11-23 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗
AU2011239466B2 (en) 2010-04-15 2015-01-22 Marine Polymer Technologies, Inc. Anti-bacterial applications of poly -N-acetylglucosamine nanofibers
KR101257228B1 (ko) * 2010-06-16 2013-04-29 주식회사 나이벡 항균 또는 항염증 활성을 가지는 펩타이드 및 이를 유효성분으로 함유하는 약제학적 조성물
MX356877B (es) * 2011-04-15 2018-06-19 Marine Polymer Tech Inc Tratamiento de enfermedades con nanofibras de poli-n-acetil-glucosamina.
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
WO2013026794A1 (en) 2011-08-19 2013-02-28 Novozymes Novel immunomodulatory peptide
JP6151981B2 (ja) * 2013-06-18 2017-06-21 一般社団法人健康科学リソースセンター 関節リウマチ患者における生物学的製剤の有効性の予測方法
US11111284B2 (en) 2014-08-21 2021-09-07 The General Hospital Corporation Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing
GB201603653D0 (en) * 2016-03-02 2016-04-13 Cambridge Entpr Ltd Combination Therapy
BR112018071972A2 (pt) 2016-04-29 2019-02-26 Defensin Therapeutics Aps métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos.
US11413328B2 (en) * 2016-12-13 2022-08-16 Novozymes A/S Methods for treating inflammatory conditions of the lungs
KR102631542B1 (ko) 2018-03-14 2024-02-01 서울대학교산학협력단 염증 감소능 및 줄기세포로부터 연골세포로의 분화 촉진능을 가지는 이중 기능성 펩타이드 및 이의 용도
KR102631543B1 (ko) * 2018-03-14 2024-02-01 서울대학교산학협력단 세포 투과능 및 근육 재생능을 가지는 이중 기능성 펩타이드 및 이의 용도
WO2020046002A1 (ko) * 2018-08-31 2020-03-05 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR102244161B1 (ko) 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
KR20240138109A (ko) 2022-01-28 2024-09-20 존슨 앤드 존슨 컨수머 인코포레이티드 아토피성 피부염을 예측하는 바이오마커
EP4504160A1 (en) 2022-04-04 2025-02-12 Kenvue Brands LLC Window of opportunity skin treatment regimen and composition for preventing the onset of or treating atopic dermatitis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338936B2 (en) * 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2003288507A1 (en) * 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
GB0514482D0 (en) * 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) * 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
CA2704726A1 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of a defensin peptide as a therapeutic agent
US8232248B2 (en) * 2008-07-18 2012-07-31 Novozymes Adenium Biotech A/S Treatment of rheumatoid arthritis with mammal beta defensins
CN102247591A (zh) * 2008-07-18 2011-11-23 诺维信阿德宁生物技术公司 使用哺乳动物β防御素的炎性肠病的治疗

Also Published As

Publication number Publication date
EA201170218A1 (ru) 2011-08-30
ZA201100462B (en) 2013-03-27
WO2010007165A2 (en) 2010-01-21
EP2320929A2 (en) 2011-05-18
CL2011000098A1 (es) 2011-10-07
BRPI0915780A2 (pt) 2019-03-12
CN102159232A (zh) 2011-08-17
AU2009272680A1 (en) 2010-01-21
AP2011005537A0 (en) 2011-02-28
IL210714A0 (en) 2011-03-31
WO2010007165A3 (en) 2010-06-03
NZ590466A (en) 2012-08-31
KR20110031962A (ko) 2011-03-29
KR20110044863A (ko) 2011-05-02
US20100016232A1 (en) 2010-01-21
MX2011000569A (es) 2011-02-23
CA2730674A1 (en) 2010-01-21
TW201004641A (en) 2010-02-01
JP2011528332A (ja) 2011-11-17
EP2320929B1 (en) 2019-05-29

Similar Documents

Publication Publication Date Title
NZ590466A (en) Treatment of inflammatory diseases with mammal beta defensins
JP2011528332A5 (enExample)
EA201491470A1 (ru) Композиции фактора viii и способы получения и использования подобных
MY191381A (en) Novel amino pyrimidine derivatives
BR112013028407A2 (pt) "sequências de aminoácido direcionadas em relação aos polipeptídeos de il-17a, il-17f e/ou il17-a/f compreendendo as mesmas, seus usos, polipeptídeos, e composição farmacêutica".
BR112015017338A2 (pt) anticorpos anti-il-17a e seu uso no tratamento de transtornos autoimunes e inflamatórios
UA111767C2 (uk) Дигідропіримідинізохінолінони і фармацевтичні композиції, які їх містять, для лікування запальних порушень
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
EA201190326A8 (ru) Полипептиды гормона роста и способы их получения и применения
MX2014000338A (es) Derivados de pirrolo-pirimidina novedoso.
EA201300054A1 (ru) Полипептид, обладающий активностью бета-глюкозидазы, и его применение
JP2012034702A5 (enExample)
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
EA201201126A1 (ru) Полипептид, обладающий активностью целлобиогидролазы, и его применение
BR112015022469A2 (pt) peptídeo ou análogo seu, composição, método para melhorar um sinal ou sintoma, método para estimular o crescimento de células, método para produção de uma população de células, método para aumentar o número de células, método para redução em um indivíduo diabético da tolerância à glicose debilitada, método para a promoção de neuroproteção ou regeneração nervosa, método para a promoção da regeneração, método para a inibição de inflamação, composição farmacêutica e uso de um peptídeo ou análogo seu
EA033437B9 (ru) Fc-гамма-рецептор iib и его применение для лечения или предупреждения воспалительных и/или аутоиммунных заболеваний
CL2017000478A1 (es) Compuesto de pirazolotiazol y medicamento que comprende el mismo.
AR072525A1 (es) Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo.
AR089860A1 (es) Analogos de la grelina
EA201300059A1 (ru) Полипептид, обладающий активностью сволленина, и его применение
JP2011505864A5 (enExample)
ES2529865B8 (es) USO DE COMPUESTOS DERIVADOS DE SALES DE PIRIDAZINO[1',6':1,2]PIRIDO[3,4-b]INDOLINIO COMO AGENTES ANTIINFLAMATORIOS
BR112018000155A2 (pt) moléculas de fusão
JP2010183921A5 (enExample)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal